Inozyme Pharma (INZY) to Release Quarterly Earnings on Tuesday

Inozyme Pharma (NASDAQ:INZY) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th. Analysts expect Inozyme Pharma to post earnings of ($0.42) per share for the quarter.

Inozyme Pharma Stock Down 9.2 %

INZY opened at $1.09 on Tuesday. The stock has a market cap of $70.02 million, a PE ratio of -0.70 and a beta of 1.29. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a 52 week low of $1.09 and a 52 week high of $7.80. The business’s fifty day simple moving average is $1.80 and its 200 day simple moving average is $3.49.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on INZY. Piper Sandler reduced their target price on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Wedbush reaffirmed an “outperform” rating and set a $12.00 price objective on shares of Inozyme Pharma in a research note on Friday, January 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, November 6th. HC Wainwright raised their price objective on Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company reduced their price objective on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $18.33.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.